Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.

Authors
  • Bajetta, Emilio1
  • Catena, Laura
  • Fazio, Nicola
  • Pusceddu, Sara
  • Biondani, Pamela
  • Blanco, Giusi
  • Ricci, Sergio
  • Aieta, Michele
  • Pucci, Francesca
  • Valente, Monica
  • Bianco, Nadia
  • Mauri, Chiara Maria
  • Spada, Francesca
  • 1 Institute of Oncology, Polyclinic Hospital, Monza, Italy. , (Italy)
Type
Published Article
Journal
Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Aug 15, 2014
Volume
120
Issue
16
Pages
2457–2463
Identifiers
DOI: 10.1002/cncr.28726
PMID: 24752410
Source
Medline
Keywords
License
Unknown

Abstract

The everolimus-octreotide LAR combination was active and well tolerated in these previously treated patients with advanced NETs, suggesting a possible role as first-line treatment in patients with NET.

Report this publication

Statistics

Seen <100 times